Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation.

Trial Profile

Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Acenocoumarol; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms EINSTEIN-PE
  • Sponsors Bayer
  • Most Recent Events

    • 12 Dec 2017 Results of exposure-response analysis using patient data from NCT00439777 and NCT00440193 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 29 Oct 2015 Results (n=8245) of this and EINSTEIN-DVT trial published in the Thrombosis and Haemostasis
    • 31 Mar 2014 Pooled sub-study results for the influence of prestudy heparin from the EINSTEIN DVT and EINSTEIN PE trails presented at the 63rd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top